神经中枢：阿尔茨海默病三期试验暂停：治疗性生物标志物的探索仍在继续。 - Suppr

Suppr

超能文献

NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.

作者信息

Samson Kurt

出版信息

Ann Neurol. 2010 Oct;68(4):A9-A12. doi: 10.1002/ana.22249.

DOI:10.1002/ana.22249

PMID:20976761

Abstract

摘要

相似文献

NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.

Ann Neurol. 2010 Oct;68(4):A9-A12. doi: 10.1002/ana.22249.

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

Ann Neurol. 2011 Feb;69(2):237-9. doi: 10.1002/ana.22365.

Molecule of the month. Semagacestat.

Drug News Perspect. 2008 Sep;21(7):390.

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

Biol Psychiatry. 2010 Nov 15;68(10):876-8. doi: 10.1016/j.biopsych.2010.09.020.

[Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].

Ann Dermatol Venereol. 2013 Oct;140(10):669-70. doi: 10.1016/j.annder.2013.06.003. Epub 2013 Jul 29.

Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.

Curr Opin Investig Drugs. 2009 Jul;10(7):721-30.

Lessons from a failed γ-secretase Alzheimer trial.

Cell. 2014 Nov 6;159(4):721-6. doi: 10.1016/j.cell.2014.10.016.

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Neurology. 2006 Feb 28;66(4):602-4. doi: 10.1212/01.WNL.0000198762.41312.E1.

[Gamma-secretase inhibitors and modulators].

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:83-7.

Alzheimer's failure raises questions about disease-modifying strategies.

Nat Rev Drug Discov. 2010 Oct;9(10):749-51. doi: 10.1038/nrd3288.

引用本文的文献

Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells.

J Biol Chem. 2019 Jul 19;294(29):11276-11285. doi: 10.1074/jbc.RA119.008041. Epub 2019 Jun 5.

γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct.

EMBO Mol Med. 2017 Jul;9(7):950-966. doi: 10.15252/emmm.201607265.

Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.

Drug Discov Today. 2017 Feb;22(2):223-233. doi: 10.1016/j.drudis.2016.10.010. Epub 2016 Oct 27.

The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides.

Sci Rep. 2015 Nov 16;5:16541. doi: 10.1038/srep16541.

The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study.

Neurology. 2013 Oct 15;81(16):1425-33. doi: 10.1212/WNL.0b013e3182a841c6. Epub 2013 Sep 18.

γ-Secretase inhibitors and modulators.

Biochim Biophys Acta. 2013 Dec;1828(12):2898-907. doi: 10.1016/j.bbamem.2013.06.005. Epub 2013 Jun 17.

γ-Secretase inhibition promotes fibrotic effects of albumin in proximal tubular epithelial cells.

Br J Pharmacol. 2013 Jul;169(6):1239-51. doi: 10.1111/bph.12214.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21.

Disease modifying drugs targeting β-amyloid.

Am J Alzheimers Dis Other Demen. 2012 Aug;27(5):296-300. doi: 10.1177/1533317512452034.

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2013 Jan;34(1):62-72. doi: 10.1016/j.neurobiolaging.2012.03.006. Epub 2012 Apr 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验